Search Results
Jun 10, 2026, 20:22 ET DMEGC Solar présentera ses modules photovoltaïques de nouvelle génération à Intersolar Europe 2026
destinés aux applications résidentielles et commerciales et industrielles (C&I). Le module entièrement noir G12RT-G48HBB, optimisé par la technologie ABT exclusive de DMEGC, poursuit le succès de l'entreprise sur le marché résidentiel avec une puissance maximale de 485 W. Un autre module destiné au marché
More news about: DMEGC Solar
Jun 10, 2026, 18:55 ET DMEGC Solar presentará sus módulos fotovoltaicos de última generación en Intersolar Europe 2026
INFINITY 3.0 para aplicaciones residenciales y comerciales e industriales (C&I). El módulo totalmente negro G12RT-G48HBB, mejorado con la tecnología ABT patentada de DMEGC, continúa el éxito de la compañía en el mercado residencial con una potencia máxima de 485 W. Otro módulo residencial, el G12RT-G48HBW-Extreme,
More news about: DMEGC Solar
Jun 10, 2026, 04:53 ET DMEGC Solar to Unveil Next-Generation PV Modules at Intersolar Europe 2026
3.0 modules for residential and commercial & industrial (C&I) applications. The all-black module G12RT-G48HBB, enhanced by DMEGC's proprietary ABT technology, continues the company's success in the residential market with a maximum power output of 485W. Another residential module, the G12RT-G48HBW-Extreme,
More news about: DMEGC Solar
Jun 08, 2026, 09:00 ET New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
American Diabetes Association's 86th Scientific Sessions showed that adults living with type 2 diabetes participating in Abbott's (NYSE: ABT) Healthy Food Rx "Food is Medicine" program, paired with community health worker–led coaching, experienced major improvements in healthy eating, physical
More news about: Abbott
Jun 06, 2026, 09:00 ET New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
with DKA1ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for
More news about: Abbott
May 29, 2026, 10:05 ET The Last Mile Retail Awards Celebrates Retail & Last Mile Excellence in Nashville
Discount Furniture Most Innovative Retailer – City Furniture Appliances Best Overall Appliance Retailer – Abt Electronics & Appliances Best Customer Service Experience – Best Buy Health & Fitness Best Overall
More news about: The Last Mile Retail Awards
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
Summary of Product Characteristics (SmPC).3ClinicalTrials.gov. Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY). Available at:
More news about: AbbVie
May 29, 2026, 08:00 ET AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
Summary of Product Characteristics (SmPC).3ClinicalTrials.gov. Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY). Available at:
More news about: AbbVie
May 28, 2026, 03:00 ET Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
systemsABBOTT PARK, Ill., May 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose–ketone sensing technology for people with diabetes.
More news about: Abbott
May 27, 2026, 09:00 ET Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
systemsABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.
More news about: Abbott
May 27, 2026, 07:01 ET ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
payersABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard®
More news about: Abbott
May 26, 2026, 09:00 ET Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
useABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting,
More news about: Abbott
May 06, 2026, 09:00 ET Abbott recebe aprovação da Anvisa para a válvula biológica Epic™ Max para tratar pacientes com estenose ou insuficiência da válvula aórtica
HorizonteSÃO PAULO, 6 de maio de 2026 /PRNewswire/ -- A Abbott (NYSE: ABT), líder global em cuidados para a saúde, anuncia hoje a aprovação regulatória da Anvisa (Agência Nacional de Vigilância Sanitária) para a válvula biológica
More news about: Abbott
Apr 28, 2026, 09:00 ET Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
patientsABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. This marks
More news about: Abbott
Apr 25, 2026, 12:30 ET Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
systemABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction
More news about: Abbott
Apr 23, 2026, 13:19 ET /C O R R E C T I O N -- The Last Mile Retail Awards/
Abt Health/FitnessBest Overall Health/Fitness Equipment Retailer:
More news about: The Last Mile Retail Awards
Apr 17, 2026, 15:30 ET New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
MCEDABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker,
More news about: Abbott
Apr 16, 2026, 07:30 ET Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a reported
More news about: Abbott
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate ABT-301's superior performance in enhancing immunotherapy for colorectal cancer
More news about: Anbogen Therapeutics
Apr 13, 2026, 00:00 ET AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The data demonstrate ABT-301's superior performance in enhancing immunotherapy for colorectal cancer
More news about: Anbogen Therapeutics
Apr 09, 2026, 09:00 ET New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
healthyABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults
More news about: Abbott
Apr 06, 2026, 09:00 ET Abbott recebe aprovação regulatória no Brasil de serplulimabe, novo medicamento biológico para o tratamento de câncer de pulmão de pequenas células com doença extensa, oferecendo uma nova alternativa para pacientes
significativo²SÃO PAULO, 6 de abril de 2026 /PRNewswire/ -- A Abbott (NYSE: ABT), líder global em cuidados para a saúde, anuncia a aprovação regulatória da Anvisa (Agência Nacional de Vigilância Sanitária) para serplulimabe no Brasil,
More news about: Abbott
Mar 30, 2026, 09:00 ET Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
workflowABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the
More news about: Abbott
Mar 26, 2026, 09:00 ET Abbott hosts conference call for first-quarter earnings
ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live
More news about: Abbott
Mar 24, 2026, 08:00 ET John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
Cologuard.com/TheTalkABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting beloved sitcom
More news about: Abbott